Abstract
Aims/hypothesis Metformin use has been associated with reduced incident dementia in diabetic patients in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomization (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease (AD) and potential causal mechanisms in the brain linking the two.
Methods Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA1c level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising of 527,138 middle-aged Europeans, including 71,880 AD or AD-by-proxy patients. MR estimates representing lifelong metformin use on AD and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6,601 donors) on AD was further estimated.
Results Genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA1c was associated with 4% lower odds of AD (odds ratio [OR]=0.964, 95%CI=0.982∼0.946, P=1.06×10−4) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on AD (OR=0.88, P=4.73×10−4) that was independent of AMPK. MR of expression in brain cortex tissue showed that decreased MCI-related gene, NDUFA2, expression was associated with reduced AD risk (OR=0.95, P=4.64×10−4) and less cognitive decline.
Conclusion/interpretation Metformin use is likely to cause reduced AD risk in the general population. Mitochondrial function and the NDUFA2 gene are likely mechanisms of action in dementia protection.
What is already known about this subject
Metformin is an anti-diabetic drug with repurposing potential for dementia prevention.
In a search of PubMed, Embase and clinicaltrials.gov, a few observational studies suggested the association of metformin use with reduced dementia incidence in diabetic patients
What is the key question?
What is the effect of genetically proxied metformin use on Alzheimer’s disease (AD) and cognitive function in the general population, especially for those without diabetes? Is the causal role between the two at least partly influenced by mechanisms in the brain?
What are the new findings?
In a Mendelian randomization analysis of over 527,138 individuals (71,880 AD or AD-by-proxy cases), genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA1c was associated with 14% lower odds of AD (odds ratio=0.86), where mitochondrial complex I is a key effect modifier.
Expression level of a mitochondrial complex I related gene, NDUFA2, showed an effect on reducing AD risk and less cognitive decline in brain.
How might this impact on clinical practice in the foreseeable future?
Our study predicts the efficacy of metformin on reducing AD risk and reducing cognitive decline in the general population, especially for those without diabetes.
Mitochondrial function and a mitochondrial related gene, NDUFA2, could be considered as a novel drug target for dementia prevention.
Graphical abstractTweet Effect of metformin targets reduced 4% of Alzheimer’s disease risk in non-diabetic individuals. @oldz84 @tomgaunt @mendel_random @mrc_ieu
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
J.Z. is supported by the Academy of Medical Sciences (AMS) Springboard Award, the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation and Diabetes UK (SBF006\1117). J.Z. is funded by the Vice-Chancellor Fellowship from the University of Bristol. M. X., W. W., Y. B. and G. N. are supported by the National Natural Science Foundation of China (82088102, 81970728 and 81941017) and the Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (20161307 and 20152508 Round 2). M. X., W. W., Y. B. and G. N. are members of the Innovative Research Team of High-level Local Universities in Shanghai. J.Z., V.W., G.D.S. and T.R.G. are supported by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/1 and MC_UU_00011/4). R.K.L. was supported by a Wellcome Trust PhD studentship (Grant ref: 215193/Z18/Z). MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study only used openly available human data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results. In more details, the genetic association data of the selected risk factors are available in ESM Tables. The GWAS summary statistics for the 21 primary outcomes are available from the IEU OpenGWAS database (https://gwas.mrcieu.ac.uk/). UK Biobank received ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 11/NW/0382). The analytical script of the MR analyses conducted in this study is available via the GitHub repository of the TwoSampleMR R package (https://github.com/MRCIEU/TwoSampleMR/).